German drug maker Boehringer Ingelheim has announced it is scrapping plans to win U.S. approval to market an AIDS drug. Clinical trial data collected on Nevirapine, which appears to prevent mother-to-child transmission of AIDS, may not conform to FDA regulatory requirements, the National Institute for Allergies and Infectious Diseases said.

Full Story:

Related Summaries